Clinical outcomes of direct-acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment.
Yuki TahataRyotaro SakamoriAyako UrabeRyoko YamadaKazuyoshi OhkawaNaoki HiramatsuHideki HagiwaraMasahide OshitaYasuharu ImaiTakahiro KodamaHayato HikitaTomohide TatsumiTetsuo TakeharaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2020)
The recurrence rates and patterns of HCC and overall survival rates do not differ between SVR patients receiving IFN and DAA treatments.